Healthcare consumerization is accelerating, driven by GLP-1s, telemedicine, AI and new low-friction care models. Patients are researching symptoms, seeking health information through social media and AI, and engaging with care in new ways before ever speaking with a physician. According to Princeton10 leaders Rachel Stoll and Kevin Nalty, these shifts are fundamentally changing patient expectations and creating new challenges and opportunities for pharma brands.
The discussion explores a critical gap between feeling informed and receiving a clinical diagnosis. While wellness technologies, health trackers and consumer health platforms provide more data than ever, they do not necessarily lead to accurate diagnosis or action. The speakers highlight how patients may delay care, rely on wellness tools or AI instead of clinicians, and fall out of the healthcare journey before entering the system. These evolving behaviors create friction points that traditional brand measurement often misses.
The episode also examines how pharma can rethink disease awareness, improve paths to diagnosis and treatment, and apply engagement principles from successful consumer apps. As patient expectations continue to evolve, brand teams may need to focus less on tactics and more on modernizing commercial strategy to reduce friction, support better outcomes and adapt to a rapidly changing healthcare landscape.